ICOS Antibody (ANC6C6-A3): sc-65285

ICOS Antibody (ANC6C6-A3) is a mouse monoclonal IgG1 kappa light chain antibody that detects the ICOS protein of human origin by flow cytometry (FCM). Anti-ICOS antibody (ANC6C6-A3) is available as the non-conjugated format, providing researchers with a reliable tool for studying T cell activation and immune responses. ICOS (inducible co-stimulator) plays a crucial role in enhancing T cell responses, particularly in T cell proliferation and lymphokine production. ICOS is structurally related to other key proteins in the immune system, such as CD28 and CTLA-4, which are part of a receptor family that regulates T cell activation. ICOS interaction with ligands on antigen-presenting cells is essential for optimal T cell function, providing necessary costimulatory signals that complement T cell receptor engagement. Unlike CD28, which promotes IL-2 production, ICOS stimulation leads to superinduction of IL-10 synthesis, highlighting a unique role in modulating immune responses. ICOS serves as a significant target for therapeutic interventions aimed at enhancing or regulating immune activity in various diseases, including cancer and autoimmune disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ICOS Antibody (ANC6C6-A3) References:

1. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.  |  Schwartz, RH. 1992. Cell. 71: 1065-8. PMID: 1335362
2. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7.  |  Freeman, GJ., et al. 1991. J Exp Med. 174: 625-31. PMID: 1714935
3. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.  |  Guedan, S., et al. 2018. JCI Insight. 3: PMID: 29321369
4. Distinct roles of ICOS and CD40L in human T-B cell adhesion and antibody production.  |  Liu, Z., et al. 2021. Cell Immunol. 368: 104420. PMID: 34418679
5. Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment.  |  Boggio, E., et al. 2022. Br J Haematol. 196: 1369-1380. PMID: 34954822
6. PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors.  |  Duhen, R., et al. 2022. J Clin Invest. 132: PMID: 35439168
7. PD-1 and ICOS counter-regulate tissue resident regulatory T cell development and IL-10 production during flu.  |  McGee, MC., et al. 2022. Front Immunol. 13: 984476. PMID: 36159872
8. Differential Modulation of Human M1 and M2 Macrophage Activity by ICOS-Mediated ICOSL Triggering.  |  Gigliotti, CL., et al. 2023. Int J Mol Sci. 24: PMID: 36769276
9. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.  |  Fargeas, CA., et al. 1995. J Exp Med. 182: 667-75. PMID: 7544393
10. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28.  |  Peach, RJ., et al. 1995. J Biol Chem. 270: 21181-7. PMID: 7545666
11. CTLA4 mediates antigen-specific apoptosis of human T cells.  |  Gribben, JG., et al. 1995. Proc Natl Acad Sci U S A. 92: 811-5. PMID: 7846057
12. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.  |  Hutloff, A., et al. 1999. Nature. 397: 263-6. PMID: 9930702

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-ICOS Antibody (ANC6C6-A3) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-ICOS Antibody (ANC6C6-A3) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

ICOS Antibody (ANC6C6-A3) Specifications

Alternate Product Name: ICOS

Product Clone Name: ANC6C6-A3

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: ICOS

Epitope Species: human

Product Reactivity/Detection: ICOS

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: FCM

Vialing Information: Each vial contains 100 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for ICOS Antibody (ANC6C6-A3): N/A